Kevin Sayer has been the CEO of DexCom, Inc. since 2015, where he has played a crucial role in transforming diabetes management through innovative technology. Holding a Master's degree in Accounting and Information Systems from Brigham Young University, Kevin has...

Kevin Sayer has been the CEO of DexCom, Inc. since 2015, where he has played a crucial role in transforming diabetes management through innovative technology. Holding a Master's degree in Accounting and Information Systems from Brigham Young University, Kevin has a strong background in finance and healthcare. Prior to DexCom, he served as the Chief Financial Officer of Biosensors International Group, a company focused on medical devices, enhancing his expertise in this field. Sayer is a Certified Public Accountant, which underlines his financial acumen. In 2023, his total compensation was approximately $15.7 million, reflecting both his leadership and the company's performance, where his salary was $1.1 million, a bonus of around $2 million, and vested stock valued at a whopping $13.5 million. Beyond numbers, what stands out is his steady journey at DexCom since 2007, starting from a board member to becoming the CEO, indicating a deep-rooted commitment to the company and its mission. Sayer’s involvement in shaping the future of diabetes care has proven pivotal, especially through the company’s performance metrics that focus on revenue and operational goals, which directly tie to patient care enhancements.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other DexCom CEOs

D

Kevin Sayer

CEO of DexCom

Education

Master's Degree in Accounting and Information Systems, B.A. from Brigham Young University

Field of Expertise

Finance & Banking - Finance

Sector of Economy

Healthcare

Born

November 30, 1959 - 65 years ago

CEO of DexCom for

10 years 3 months (Jan 2015 - Present)

Previous Experience

Served as President of DexCom since June 2011; served as Chief Financial Officer of Biosensors International Group, Ltd.

Rivals

Competitors/colleagues of Kevin Sayer

I

Joseph W. Dziedzic

CEO of Integer Holdings

2022 Compensation

Stock

$0.00

Salary

$1.23M

Bonus

$0.00

Other

$97.75K

Total Holdings

$34.74M

A

Robert B. Ford

CEO of Abbott

2023 Compensation

Stock

$6.92M

Salary

$1.50M

Bonus

$2.95M

Other

$3.67M

Total Holdings

$52.73M

I

Michael Levitz

CEO of Insulet

2023 Compensation

Stock

$0.00

Salary

$842.31K

Bonus

$2.03M

Other

$9.90K

Total Holdings

$14.76M

Holdings

See how much did Kevin Sayer make over time.

Kevin Sayer's holdings in DexCom, Inc., have seen significant fluctuations over the years. In 2019, his assets peaked at $44.14 million and reached an impressive $64.75 million by July 2020, showcasing the company's dynamic growth. However, the value of his...

Kevin Sayer's holdings in DexCom, Inc., have seen significant fluctuations over the years. In 2019, his assets peaked at $44.14 million and reached an impressive $64.75 million by July 2020, showcasing the company's dynamic growth. However, the value of his holdings has varied since then. By October 2023, they were around $27.62 million. Throughout this period, Sayer’s ownership remained a crucial indicator of his investment in the company’s future, often mirroring the company's overall market performance. This alignment not only motivates Sayer to succeed but also aligns well with shareholder interests, as evidenced by the increased focus on DexCom's strategic goals and performance metrics, particularly in the growing diabetes care market.

Total Stock Sold

$80.51M

DXCM

$80.51M

3,417,381 DXCM shares

What if they kept their stock?

If Kevin Sayer didn't sell their stock, today they would have:
Extra DXCM3,417,381 shares worth $220.43M.
This is 173.78% and $139.92M more than what they got when they sold the stock.

Charitable Transactions

DXCM

211,260 shares

DXCM

Recent Charitable Transactions

DXCM

10,000 shares

DXCM

Jan 18, 2023

Charity

DXCM

3,000 shares

DXCM

Nov 15, 2021

Charity

DXCM

10,000 shares

DXCM

Mar 8, 2021

Charity

DXCM

13,474 shares

DXCM

Mar 11, 2020

Charity

DXCM

20,841 shares

DXCM

Aug 15, 2019

Charity

DXCM

500 shares

DXCM

Dec 14, 2016

Charity

Insider Trading

See recent insider trades of Kevin Sayer.

DXCM

$2.29M

DXCM at $70.38/share

Mar 12, 2025

Sale

DXCM

85,490 shares

DXCM

Mar 8, 2025

Received

DXCM

$2.90M

DXCM at $86.91/share

Jan 28, 2025

Sale

DXCM

68,503 shares

DXCM

Jan 28, 2025

Received

DXCM

$6.87M

DXCM at $138.33/share

Apr 8, 2024

Sale

DXCM

$10.79M

DXCM at $133.19/share

Mar 12, 2024

Sale

DXCM

51,692 shares

DXCM

Mar 8, 2024

Received

DXCM

$4.61M

DXCM at $123.63/share

Jan 12, 2024

Sale

DXCM

$72.71

DXCM at $0.00/share

Jan 12, 2024

Received

DXCM

$2.39M

DXCM at $114.64/share

Apr 3, 2023

Sale

Compensation History

See how much did Kevin Sayer make over time.

In 2023, Kevin Sayer's total compensation reached approximately $15.7 million. His salary was about $1.1 million, accompanied by a bonus of around $2 million, hitting 185% of his target allocation. The bulk of his earnings came from vested stocks worth roughly $13.5 million. This high figure reflects his effective leadership and the company's strong performance in the healthcare sector. Sayer's compensation since he took over has reflected a well-structured performance-based pay system, ensuring that his interests align closely with the success of DexCom. The compensation plan not only rewards him for meeting revenue and operational goals but also indicates a long-term commitment from the company to retain effective leadership.

Year

2023

Total Compensation

$16.73M

Salary

$1.09M

Board Justification

The compensation philosophy is designed to attract and retain executive talent while aligning the interests of executives with those of stockholders through performance-based incentives.

Bonus

$1.99M

Board Justification

Annual cash bonus awarded under the 2023 Bonus Plan based on the achievement of financial and individual performance objectives.

Other

$143.54K

Board Justification

Includes personal security arrangements and tax reimbursements related to the attendance of the CEO's spouse at company events.

Restricted Stock

$13.51M(108.84K PSU)

Board Justification

Performance-based stock units (PSUs) that vested based on the achievement of the Corporate Performance Metric and Relative TSR Performance Metric for fiscal 2023.

Performance Metrics

The performance metrics for the CEO's compensation in 2023 included adjusted revenue, non-GAAP operating margin, and strategic operational goals.

Other DexCom CEOs

Here are other CEOs of DexCom

Andrew P. Rasdal

Ex-CEO of DexCom

June 2007 - February 2007